GetTopicDetailResponse(id=260c1242347d, topicName=序貫化療, introduction=, content=非小細胞肺癌 序貫化療, image=null, comments=0, allHits=278, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Feb 15 14:51:31 CST 2025, time=2025-02-15, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=501496, tagList=[TagDto(tagId=501496, tagName=序貫化療)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2252042, encodeId=3f7c225204268, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細胞肺癌#</a> <a href='/topic/show?id=260c1242347d' target=_blank style='color:#2F92EE;'>#序貫化療#</a>, objectTitle=EGFR突變/ALK融合Ⅲ期非小細胞肺癌新輔助靶向序貫化療的長期生存如何？隨訪超5年數(shù)據(jù)揭曉, objectType=article, longId=863360, objectId=88ca8633605a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241114/1731577202553_8538692.png, objectUrl=/article/show_article.do?id=88ca8633605a, replyNumber=0, likeNumber=31, createdTime=2025-02-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=88ca8633605a, moduleTitle=EGFR突變/ALK融合Ⅲ期非小細胞肺癌新輔助靶向序貫化療的長期生存如何？隨訪超5年數(shù)據(jù)揭曉, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=88ca8633605a)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-02-15發(fā)表于陜西省
